https://pharmacopedia.wiki/index.php?action=history&feed=atom&title=Celecoxib
Celecoxib - Revision history
2026-06-10T10:00:51Z
Revision history for this page on the wiki
MediaWiki 1.46.0-beta
https://pharmacopedia.wiki/index.php?title=Celecoxib&diff=6677&oldid=prev
MDElliottMD: parser-claude: Celecoxib MedTemplate refill, Top 300 stub upgrade
2026-05-23T07:01:09Z
<p>parser-claude: Celecoxib MedTemplate refill, Top 300 stub upgrade</p>
<table style="background-color: #fff; color: #202122;" data-mw-interface="">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:01, 23 May 2026</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">{{Stub}}</del></div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{MedTemplate</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{MedTemplate</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| generic = Celecoxib</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| generic <ins style="font-weight: bold; text-decoration: none;"> </ins>= Celecoxib</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| brand <del style="font-weight: bold; text-decoration: none;"> </del>= Celebrex</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| brand <ins style="font-weight: bold; text-decoration: none;"> </ins>= Celebrex <ins style="font-weight: bold; text-decoration: none;">(oral capsules), Elyxyb (oral solution, for acute migraine)</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| classes = NSAID, COX-2 <del style="font-weight: bold; text-decoration: none;">selective</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| structure =</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| <del style="font-weight: bold; text-decoration: none;">intro </del> = <del style="font-weight: bold; text-decoration: none;">Celecoxib is a selective </del>COX-2 inhibitor, in the COX-2 selective <del style="font-weight: bold; text-decoration: none;">subclass of </del>non-<del style="font-weight: bold; text-decoration: none;">steroidal anti</del>-<del style="font-weight: bold; text-decoration: none;">inflammatory drugs (NSAIDs)</del>.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| classes <ins style="font-weight: bold; text-decoration: none;"> </ins>= <ins style="font-weight: bold; text-decoration: none;">[[:Category:NSAIDs|Non-steroidal anti-inflammatory (</ins>NSAID, <ins style="font-weight: bold; text-decoration: none;">selective </ins>COX-2<ins style="font-weight: bold; text-decoration: none;">)]], [[:Category:Analgesics|Analgesic]]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| uses = <vote slug="osteoarthritis-use">Osteoarthritis (FDA)</vote>, <vote slug="rheumatoid-arthritis-use">Rheumatoid arthritis (FDA)</vote>, <vote slug="juvenile-ra-use">Juvenile rheumatoid arthritis (FDA, ≥2 years)</vote>, <vote slug="ankylosing-spondylitis-use">Ankylosing spondylitis (FDA)</vote>, <vote slug="acute-pain-celecoxib-use">Acute musculoskeletal pain (FDA)</vote>, <vote slug="dysmenorrhea-use">Primary dysmenorrhea (FDA)</vote>, <vote slug="fap-adjunct-use">Familial adenomatous polyposis (FDA, adjunct to surgery and surveillance)</vote>, <vote slug="acute-migraine-celecoxib-use">Acute migraine (Elyxyb oral solution, FDA)</vote></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| starting_dose = Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| preparations = Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| fda_max = 400 mg/day for chronic indications; higher for short-term acute pain</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| pill_id =</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| routes = Oral</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| onset = 30-60 minutes</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| duration = 12-24 hours</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| halflife = ~11 hours<ref name="celebrex-label">FDA Prescribing Information, Celebrex (celecoxib), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020998s053lbl.pdf</ref></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| <ins style="font-weight: bold; text-decoration: none;">bioavailability </ins> = <ins style="font-weight: bold; text-decoration: none;">~99% (oral)<ref name="celebrex-label" /></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| pregnancy = Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)<ref name="celebrex-label" /></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| legal = [[USLegal:Prescription only|Rx-only]] in US</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| mechanism = <vote slug="celecoxib-mech-claim">Selective </ins>COX-2 inhibitor, <ins style="font-weight: bold; text-decoration: none;">the only such NSAID </ins>in <ins style="font-weight: bold; text-decoration: none;">widespread US use after </ins>the <ins style="font-weight: bold; text-decoration: none;">withdrawals of rofecoxib (Vioxx, 2004) and valdecoxib (Bextra, 2005). </ins>COX-2 <ins style="font-weight: bold; text-decoration: none;">selectivity reduces gastrointestinal mucosal injury compared to non-</ins>selective <ins style="font-weight: bold; text-decoration: none;">NSAIDs, the principal pharmacological selling point, while the PRECISION trial (2016) demonstrated cardiovascular </ins>non-<ins style="font-weight: bold; text-decoration: none;">inferiority versus ibuprofen and naproxen, validating continued use.</vote> CYP2C9 substrate; CYP2C9 poor metabolizers may have higher exposure and benefit from a lower starting dose. Contains a sulfonamide moiety that has historically prompted caution in patients with sulfa antibiotic allergy, though the chemistry differs from antimicrobial sulfonamides and cross-reactivity is debated<ref name="celebrex</ins>-<ins style="font-weight: bold; text-decoration: none;">label" /></ins>.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>}}</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== References ==</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><references /></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:NSAIDs]]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:Analgesics]]</ins></div></td></tr>
</table>
MDElliottMD
https://pharmacopedia.wiki/index.php?title=Celecoxib&diff=4485&oldid=prev
MDElliottMD: Create stub for Celecoxib (linked from Category:NSAIDs Members section)
2026-05-18T02:50:01Z
<p>Create stub for Celecoxib (linked from Category:NSAIDs Members section)</p>
<p><b>New page</b></p><div>{{Stub}}<br />
{{MedTemplate<br />
| generic = Celecoxib<br />
| brand = Celebrex<br />
| classes = NSAID, COX-2 selective<br />
| intro = Celecoxib is a selective COX-2 inhibitor, in the COX-2 selective subclass of non-steroidal anti-inflammatory drugs (NSAIDs).<br />
}}</div>
MDElliottMD